1. Clinical remission at 52 weeks was similar between ustekinumab and adalimumab. 2. Patient-reported outcomes of stool frequency and abdominal ...
1. Compared to a placebo (withdrawal) group, patients maintained on subcutaneous risankizumab had greater rates of clinical remission. 2. Adverse ...
1. The risankizumab group showed greater clinical remission and endoscopic response rates compared to placebo across the ADVANCE and MOTIVATE ...
1. At weeks 10 and 58, more patients in the filgotinib 200 mg group experienced clinical remission compared with the ...
1. In children with chronic, non-bloody diarrhea and abdominal pain, a clinical prediction tool using symptoms, C-reactive protein (CRP), hemoglobin, ...
Childhood-onset inflammatory bowel disease (IBD) typically has a more severe course than adult-onset IBD, and has been found to be ...
Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis Diagnosing multiple sclerosis (MS) is challenging, ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.